Category: iCad Inc.
Shares of medical device company iCad soar nearly 36% on a Medicare reimbursement nod.
iCad (NSDQ:ICAD) shares nearly doubled their value on Wall Street today after the medical device company said the Centers for Medicare & Medicaid approved a big increase in the reimbursement rate for its Xoft Axxent brachytherapy device.
HeartWare announced that it completed enrollment in a 450-patient clinical trial considering its HVAD pump as a destination therapy for patients with advanced heart failure; also, 2011 was a good year for angel investment; Bayer considers ditching diabetes business; iCad gets a stay of execution from Nasdaq delisting; INC Research expands a electronic data management partnership with Medidata; and Kimberly Clark renews a sterilization wrap contract with HealthTrust; plus, a Funding Roundup and analysts' ups and downs.
HeartWare International (NSDQ:HTWR) completed enrollment in a 450-patient pivotal trial considering its ventricular assist system as a destination therapy for patients with advanced heart failure.
The top executives at Abbott see their pay packages decline by a collective 24%; also, Allezoe replaces suspect secretary White; Stereotaxis COO/CTO steps down; and iCad holds on to marketing SVP.
The top brass at Abbott (NYSE:ABT) saw their 2011 pay packages reduced by a collective 23.9%, ranging from a 6.1% cut for chairman & CEO Miles White to a whopping 26.9% hit for pharma head Richard Gonzalez.
The venture capital industry backs a push for passage of a bill that would make it easier for small companies to go public; also, VCs shift focus from high-tech med-tech; S&P affirms Boston Scientific's BBB rating; Allezoe CEO gets threats over PR policy; angels in America spent more on device makers last year; Flextronics buys Stellar Microelectronics; Philips Healthcare wins U.S. Army training contract; OTC exchange lists Avita Medical; iCad wins NASDAQ reprieve; Premier issues new GPO deals; plus, a Funding Roundup and analysts' ups and downs.
The National Venture Capital Assn. is spearheading a drive to get a bill through the U.S. Senate that would make it easier for small companies to raise money by going public.
The "IPO On Ramp" measure would ease the regulatory requirements for IPOs and temporarily reduce the reporting burdens imposed by the Sarbanes-Oxley Act.
Boston Scientific reconfigures its employee bonus program to allocate rewards from a single company-side pool, the value of which is tied to the company's overall performance for the year.
Boston Scientific (NYSE:BSX) employees could see their annual bonus payments shrink or grow based on the device maker's adjusted earnings per share and global sales by the end of the year, thanks to a new performance incentive plan for 2012.
The Natick, Mass.-based med-tech titan reconfigured its employee reward system, tying the total potential payout for all regions and division into a single pool, the value of which fluctuates along with the company's performance in 2012.
Angeion makes up for sagging European sales by focusing on group purchasing organizations and service revenues in Q1; also, Natus Medical's earnings plunge; Mindray posts big boosts to top, bottom lines; iCad narrows quarterly losses; MiMedx sales soar in 2011; InSite's sales slide, losses widen; Exactech's bottom line shrinks; Viking boosts sales, widens losses; MedPro cuts losses; and Alphatec dives deeper into the red.
Angeion Corp. (NSDQ:ANGN) narrowed its 1st-quarter losses despite flat sales for the 3 months ended Jan. 31.
Although dragged down by a tough European climate, focusing on group purchasing organization and service revenues kept the company's sales from sliding, the cardiorespiratory diagnostic systems maker said.
Conceptus Inc. swaps $50 million worth of 2.25% convertible senior notes due 2027 for 5% notes due 2031.
Conceptus (NSDQ:CPTS) swapped out $50 million worth of 2.25% senior notes due 2027 from a select group of holders, exchanging them for 5% notes due 2031, regulatory filings show.
The principal amount on the new notes was an even swap for the originals, which was determined in individual negotiations between Conceptus and the holders.
